ABSTRACT
Objective To compare the use of solifenacin and trospium in treatment of overactive bladder (OAB).Methods This prospective study was conducted on patients diagnosed with OAB who presenting to the Department of urology,Changzhou No.3 People's Hospital between March 2015 and May 2016.Patients were randomized into 2 groups.Group A (n =40) received 5 mg solifenacin once daily,while Group B (n =39) received 20 mg trospium twice daily.All the patients' OAB symptom scores (OABSS) in weeks 0,4,and 12 were recorded.In addition,side effects of the drugs were evaluated.Results Average OABSS was determined as:9.3 ± 2.6 (Group A) and 10.2±1.9 (Group B) at week0;2.5±1.3 (GroupA) and 2.7±1.4 (Group B) at week4;and 1.4±0.5 (Group A) and 1.3 ± 0.6 (Group B) at week 12.In addition,no statistically significant difference was found between the scores (P =0.084,P =0.512 and P =0.423).The discontinuation rate of medication due to its side effects was 0 (0％) for Group A,and 5 (12.8％) for Group B.Intragroup changes in the scores 0 weeks-4 weeks,0 weeks-12 weeks and 4 weeks-12 weeks values was statistically significant in both groups (P =0.000).Conclusion No significant difference was found between the OABSS of these 2 drugs.However,discontinuation of drugs due to side effects was more frequent in trospium.
ABSTRACT
@#Trospium chloride is an anticholinergic agent with predominantly peripheral nonselective antimuscarinic activity and water solubility. It has potential therapeutic value in decreasing detrusor contracivity and tonity, so as to increase predominantly mean maximal bladder capacity and compliance. Multicenter studys showed that the tolerability and efficacy of trospium chloride was as same as oxybutynin and better than toterodine. Adverse events of trospium chloride is the same as other anticholinergic agents, however its specially constitutional feature so as not to have toxicity to central nervous system. Trospium chloride has potential therapeutic value in the neurourological rehabilitation.